IMMU — Mendus AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK346.22m
- SEK304.26m
Brief: Mendus Announces USPTO Patent Grant For Vididencel In Ovarian Cancer
Brief: Mendus Q1 Operating Profit SEK -30.222 Million
Brief: Mendus Appoints Tariq Mughal As Chief Medical Officer
Brief: Mendus: No Dividend To Be Paid
Brief: Mendus And UMCG Announce Positive Topline Data From Alison Trial
Brief: Mendus: Data From Advance II Phase 2 Trial Demonstrate Durable Survival Of AML Patients Treated With Vididencel
Brief: Mendus Q3 Net Loss Narrows To SEK 23.0 Mln
Brief: Mendus Q2 Net Loss At SEK 38.2 Million
Brief: Mendus Announces Collaboration With Institut Bergonié
Brief: Mendus Says Alison Trial Reaches Primary Objective
Brief: Mendus: Reverse Share Split
Brief: Sven Andreasson Is Elected As Chairman Of Mendus
Brief: Mendus Q1 Net Loss Widens To SEK 35.6 Mln
Brief: Mendus Raises About SEK 69.1 Mln Through Warrants
Brief: Mendus Q4 Loss For Period Narrows To SEK 41.2 Mln
Brief: Mendus Announces Positive Survival Data From Phase 2 Advance Ii Trial Evaluating Vididencel As Maintenance Therapy For Aml At Ash 2023
Brief: Mendus Q3 Loss For Period Narrowed To SEK 26.4 Mln
Brief: Mendus Receives U.S. FDA Fast Track Designation For Vididencel In Acute Myeloid Leukemia
Brief: Mendus Q2 Operating Loss Narrows To SEK 27.7 Mln